On the morning of August 26, 2026, a new paper was published in Nature Medicine.1
The study provides an observational yet carefully designed analysis suggesting that the recombinant shingles vaccine Shingrix lowers cardiovascular burden. Maxime Taquet and his team at the University of Oxford capitalized on a rapid vaccine transition that occurred in the United States between 2017 and 2018. For one year, the older live vaccine Zostavax was dominant; by the following year, nearly everyone had transitioned to Shingrix. The researchers compared the two groups. Shingles is a painful rash caused by the reactivation of the chickenpox virus later in life. Recommended for adults over 50 in many regions, Shingrix contains a viral protein alongside an immune-boosting adjuvant and is administered in two doses. The older Zostavax contained a weakened live virus and was phased out in the United States after 2017.
- Oxford researchers treated the rapid U.S. vaccine transition as a natural experiment, following two matched groups of adults over 60 for seven years.
- The Shingrix group experienced a 9 percent reduction in overall cardiovascular burden, a 12 percent drop in heart failure, and a 10 percent decrease in ischemic heart disease.
- An analysis of the same dataset last year reported a 17 percent reduction in dementia risk, though the underlying mechanism remains unknown.
- A randomized trial involving 160,000 participants is currently underway in Denmark, meaning it is premature to view the vaccine as a substitute for standard heart medications before those results arrive.
Why is this study different from previous research?
Previous studies compared individuals who received the shingles vaccine with those who did not, but vaccinated individuals generally tend to live healthier lifestyles and visit doctors more frequently. This confounding factor tended to weaken the reliability of past results. Taquet's team instead placed the two vaccination periods side by side. Because the transition occurred very rapidly, both groups shared similar age demographics, healthcare systems, and historical timeframes.1 Individuals vaccinated between April and September 2017 were matched with those vaccinated during the same months in 2018, encompassing roughly 72,000 participants in total, all aged 60 and older.
The primary composite endpoint was defined as ischemic heart disease, heart failure, or ischemic stroke. Over a seven-year follow-up period, the cardiovascular burden in the Shingrix group decreased by 9 percent. Declines included a 12 percent drop in heart failure, a 10 percent decrease in ischemic heart disease, and a 7 percent reduction in atrial fibrillation. Among men, a 12 percent reduction in ischemic stroke was observed, while other vascular outcomes showed no distinct differences.1
How clinically significant are these percentage reductions?
A 9 percent decrease might initially appear modest.
However, heart failure and coronary disease are exceptionally widespread among older populations. The authors note that if this effect is confirmed, it could delay hundreds of thousands of cases globally.2 At the 3.5-year midpoint, 10.9 percent of the Zostavax group had experienced heart failure, stroke, or blocked coronary arteries, compared to 9.6 percent in the Shingrix group. Last year, the same research team reported using the same dataset to show that Shingrix reduced dementia risk by 17 percent, while extending the pre-diagnosis period for those who eventually developed dementia by an average of 164 days.3 Discovering simultaneous heart and brain protective signals tied to the same vaccine has significantly heightened scientific interest.
Does this study provide definitive proof of cardiovascular protection?
This study is not a randomized controlled trial.
It remains an observational study comparing two vaccination periods. Furthermore, the protective effect appears to wane over time, as the difference at the end of seven years is less pronounced than at 3.5 years.1 The AS01 adjuvant contained within Shingrix successfully enhances immunity, and some researchers hypothesize that this might temporarily suppress chronic inflammation, though this biological chain of events remains unproven. A randomized clinical trial is currently underway in Denmark involving 160,000 individuals aged 65 and older, who have been randomly assigned to receive either Shingrix or no vaccine, with researchers evaluating both dementia and cardiovascular outcomes.2 GSK is also conducting a second dementia-focused trial in Finland. While Shingrix is widely accessible through private healthcare and immunization programs in many regions, this specific study relies entirely on U.S. health records rather than localized population data.
Receiving the shingles vaccine already effectively lowers the risk of painful rashes and post-herpetic neuralgia, making potential cardiovascular and dementia protection an encouraging secondary benefit. However, it is not yet time to write prescriptions for Shingrix as a substitute for heart medication. Until the results of the Danish trial are published, the most accurate takeaway is that the August 26, 2026, study published in Nature Medicine (DOI 10.1038/s41591-026-04606-0) reports a 9 percent reduction in cardiovascular burden over a seven-year follow-up, and a 160,000-person trial is already underway to verify these findings through randomized methodology.
Notes and Sources
- Corsi-Zuelli, F., Li, F., Upthegrove, R. et al. (2026). "Recombinant shingles vaccination and the risk of cardiovascular events." Nature Medicine. DOI: 10.1038/s41591-026-04606-0. ↩
- Cohen, J. (2026). "Shingles vaccine linked to reduced heart risks." Science. DOI: 10.1126/science.zfnm2n3. ↩
- Corsi-Zuelli, F., Li, F., Upthegrove, R. et al. (2024). "The recombinant shingles vaccine is associated with lower risk of dementia." Nature Medicine. DOI: 10.1038/s41591-024-03201-5. ↩
